Modern Health, February 29, 2016. National Center for Health Research’s president Dr. Diana Zuckerman advises that the warning label on Essure implant contraceptive and the studies to be performed on Essure by Bayer, the company that makes the product, must both be under close watch.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
2016 Foremother and Health Policy Heroes Awards Luncheon Invitation
February 26, 2016. Find out the details for NCHR’s 2016 Awards Luncheon honoring women for a lifetime of breaking down barriers.
Read More »Critics See Accountability Risk If FDA Rule Changes Take Hold
Star Tribune, February 14, 2016. A move to relax labeling requirements for drugs and medical devices has some patient advocates concerned that people will have a tougher time holding manufacturers accountable for injuries caused by their products.
Read More »FDA Aims to Speed Clinical Trials and Improve Device Safety Through Post-Market Evaluation
Inside Health Policy, February 16, 2016. FDA’s device center chief Jeff Shuren highlighted the benefit a robust National Device Evaluation System could have in bolstering the agency’s ability to monitor devices in real-time.
Read More »FDA is Failing to Properly Track Drugs
Legalreader, February 8, 2016. Federal investigators from the Government Accountability Office (GAO) came to the conclusion that the FDA is not doing well at one of its main responsibilities.
Read More »